publication date: Jul. 6, 2018
Clinical Roundup Tecentriq + Abraxane reduced risk of disease worsening, death in triple negative breast cancer
Genentech, a member of the Roche Group, announced that phase III IMpassion130 study met its co-primary endpoint of progression free survival.
Results demonstrated that the combination of Tecentriq (atezolizumab) plus chemotherapy (Abraxane), as an initial treatment, significantly reduced the risk of disease worsening or death in people with metastatic or unresectable locally advanced triple negative breast cancer. Overall survival is encouraging in the PD-L1 positive population at this interim analysis, and follow up will continue until the next planned analysis.
Safety in the Tecentriq plus nab-paclitaxel arm appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination. Results will be presented at an upcoming medical meeting and will be submitted to global health authorities, including FDA and European Medicines Agency.
This is the third positive phase III study that includes Tecentriq and nab-paclitaxel as part of a treatment regimen. Currently, Genentech has seven ongoing phase III studies investigating Tecentriq in TNBC.
IMpassion130 study is a phase III multicenter, randomized, double-blind study evaluating the efficacy, safety, and pharmacokinetics of Tecentriq and nab-paclitaxel compared with placebo in combination with nab-paclitaxel in people with locally advanced or metastatic TNBC who have … Continue reading Tecentriq + Abraxane reduced risk of disease worsening, death in triple negative breast cancer
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.